Key result
PVI-only redo ablation achieves ~70% freedom from recurrent AF in patients without EGF-identified sources.
Why the study?
Despite a trend toward PVI-only ablation strategies for persistent AF, the success of a PVI-only strategy in a redo persistent or longstanding persistent AF population remained to be examined.
Does the presence of EGF-identified sources affect the success of PVI-only ablation in patients with redo persistent AF?
RCT (n=46)
1:1
Yes
Does the presence of EGF-identified sources affect the success of PVI-only ablation in patients with redo persistent AF?
Answers are grounded in this paper and cite their sources.
In patients undergoing redo ablation for persistent AF, a PVI-only strategy is significantly less effective in those with EGF-identified active sources compared to those without sources.
BACKGROUND: Since the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II (STAR-AF II), there has been a trend toward pulmonary vein isolation (PVI)-only ablation strategies for persistent atrial fibrillation (PeAF). Electrographic flow (EGF) mapping can identify active sources of atrial fibrillation (AF) and estimate the electrographic flow consistency (EGFC) of wavefront propagation through substrate, revealing functional AF mechanisms. OBJECTIVE: We sought to examine the success of a PVI-only ablation strategy for a redo PeAF/longstanding PeAF population. METHODS: Electrographic Flow-Guided Ablation in Redo Patients With Persistent Atrial Fibrillation (FLOW-AF [NCT04473963]) prospectively enrolled patients with nonparoxysmal AF undergoing redo ablation at 4 centers. One-minute EGF recordings using 64-pole basket catheters were obtained both pre-PVI and post-PVI following a 20-minute wait and confirmation of electrical isolation of veins. Patients with EGF-identified sources were randomized 1:1 to EGF-guided source ablation vs PVI-only. Patients with no sources were not randomized and mostly received PVI only. After PVI only, Group 1 had 70% (16 of 23) freedom from recurrent AF (FFAF) within 1 year vs Group 2 with 35% (8 of 23), P = .018. In addition, patients with high electrographic flow consistency (EGFC) indicative of healthy or normal substrate had 67% (10 of 15) FFAF vs 45% (14 of 31) in those with low EGFC suggestive of abnormal substrate, P = .011. CONCLUSION: Success rates in no-sources patients receiving PVI only are better than in those with sources randomized to PVI only. For the clinically heterogenous population of patients with PeAF, the presence of EGF-identified sources matters clinically, and PVI only will not be enough for all patients.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2024) conducted an RCT in Persistent atrial fibrillation (n=46). PVI-only ablation in patients without EGF-identified sources vs. PVI-only ablation in patients with EGF-identified sources was evaluated on Freedom from recurrent AF (FFAF) within 1 year (p=0.018). In patients with persistent AF undergoing redo ablation, a PVI-only strategy yielded 70% freedom from recurrent AF at 1 year in those without EGF-identified sources versus 35% in those with sources (P=0.018).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: